ANI Pharma (ANIP) Tops Q1 EPS by 25c, Revenues Beat; Reaffirms FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ANI Pharmaceuticals Reports First Quarter 2019 Results and Reaffirms Guidance
May 9, 2019 8:30 AM EDTBAUDETTE, Minn., May 9, 2019 /PRNewswire/ --
For the first quarter 2019:
Net revenues of $52.9 million, an increase of 14% versus 2018 GAAP net income of $0.4 million and diluted GAAP earnings per share of $0.04 Record adjusted non-GAAP EBITDA of $22.3 million Adjusted non-GAAP diluted earnings per share of $1.30ANI Pharmaceuticals, Inc. ("ANI")Â (NASDAQ: ANIP) today reported its financial results for the three months ended March 31, 2019 and reaffirmed its 2019 financial guidance. The Company will host its earnings conference call this morning, May 9,... More
